Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering novel, genetically validated therapies for ...
US clinical stage biotech Alector saw its shares tumble 35% to $2.57 by close of trading yesterday, as it announced ...
Mizuho Securities analyst Graig Suvannavejh has maintained their bullish stance on ALEC stock, giving a Buy rating today.Don't Miss our Black ...
GlobalData on MSN1d
Alector stock drops after Alzheimer’s drug fails in Phase II trial"Alector stock drops after Alzheimer’s drug fails in Phase II trial" was originally created and published by Clinical Trials ...
Alector's AL002 fails in Phase 2 Alzheimer's trial, halting extension study; focus shifts to other programs as workforce is ...
Analyst Andrew Fein of H.C. Wainwright maintained a Buy rating on Alector (ALEC – Research Report), reducing the price target to $7.00.Don't ...
Alector is kicking off a resource realignment effort that will include a workforce reduction of around 17%. The biotech ...
Alector’s AbbVie-partnered Alzheimer's asset has failed to slow disease progression in a phase 2 study, the latest in a ...
Alector Therapeutics, working with AbbVie, was testing whether modulating immune cells in brain would slow Alzheimer's ...
Shares of Alector tumbled in after-hours trading after the company said its Alzheimer drug candidate, AL002, failed to meet its phase 2 primary endpoint of slowing clinical progression of the disease.
In October 2024, Alector published a manuscript titled“Preclinical and first-in-human evaluation of AL002, a novel TREM2 agonistic antibody for Alzheimer's disease” in Alzheimer's Research ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback